These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 15972862)
1. The lessons of Vioxx--drug safety and sales. Waxman HA N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862 [No Abstract] [Full Text] [Related]
2. Vioxx doctors wooed by Merck are now its foes. Tesoriero HW Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911 [No Abstract] [Full Text] [Related]
3. The lessons of Vioxx. Frazier KC N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497 [No Abstract] [Full Text] [Related]
4. [Really only Vioxx?]. Heinzl S Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229 [No Abstract] [Full Text] [Related]
5. How to avoid another 'Vioxx'. Frantz S Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595 [No Abstract] [Full Text] [Related]
6. Raising the safety bar--the FDA's coxib meeting. Okie S N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221 [No Abstract] [Full Text] [Related]
8. Tailoring arthritis therapy in the wake of the NSAID crisis. Olsen NJ N Engl J Med; 2005 Jun; 352(25):2578-80. PubMed ID: 15972863 [No Abstract] [Full Text] [Related]
9. The Vioxx fallout. Palmer K Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592 [No Abstract] [Full Text] [Related]
18. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex. Epstein RA Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898 [No Abstract] [Full Text] [Related]
19. Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Couzin J Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414 [No Abstract] [Full Text] [Related]
20. Merck withdraws Vioxx; FDA issues public health advisory. FDA Consum; 2004; 38(6):11. PubMed ID: 15675020 [No Abstract] [Full Text] [Related] [Next] [New Search]